Dhuwit awis saben lembar saham okyopharma.com (OKYO)

The reliability of OKYO Pharma Limited (OKYO) is guaranteed by competent management with a transparent approach to OK-101 trials. The current cash per share level on the GURU.Markets chart confirms this, where the 0.40 mark characterizes this parameter. Stability is further bolstered by developments for the mass ophthalmology and neuropathic pain markets, as well as operations in the safe, sanction-protected jurisdictions of the US and UK.
Rincian analitis perusahaan OKYO Pharma Limited

A conservative approach to analyzing OKYO Pharma Limited (OKYO) is based on an assessment of financial stability. This metric determines the volume of liquid assets per common share. By analyzing the current cash per share, an investor can see the company's margin of safety. For a biotech firm, this is critically important when funding trials for the OK-101 drug. Sufficient funds guarantee the completion of research without the need for an emergency share issuance.